Clinical trial
Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal…
NCT00078468 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00078468 |
|---|---|
| Title | Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment |
| Official title | A Phase 2 Open-Label Multicenter Study Of The Garft Inhibitor AG2037 In Patients With Metastatic Colorectal Cancer Who Failed Treatment With A 5-Fluorouracil/Leucovorin Regimen. |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Neoplasms |
| Intervention type | Drug |
| Interventions | PELITREXOL/AG-2037 |
| Enrollment | 56 |
| Start date | Dec 1, 2003 |
| Completion | Sep 1, 2004 |
| First posted | Mar 2, 2004 |
| Last update posted | Nov 9, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: